Search Results - "Van Devanter, Donald R."

State of progress in treating cystic fibrosis respiratory disease by Flume, Patrick A, Van Devanter, Donald R

“…Since the discovery of the gene associated with cystic fibrosis (CF), there has been tremendous progress in the care of patients with this disease. New…”
Get full text

Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis by Elborn, J Stuart, Flume, Patrick A, Van Devanter, Donald R, Procaccianti, Claudio

“…People with cystic fibrosis (CF) are highly susceptible to bacterial infections of the airways. By adulthood, chronic ( ) is the most prevalent infective…”
Get full text

Antimicrobial resistance in cystic fibrosis: Does it matter? by Flume, Patrick A., Waters, Valerie J., Bell, Scott C., Van Devanter, Donald R., Stuart Elborn, J.

Get full text

Antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis by Van Devanter, Donald R

Get more information

The Cystic Fibrosis Survival Gap: Why Do Canadians Fare Better Than Americans? by Flume, Patrick A, VanDevanter, Donald R

“…The Cystic Fibrosis Foundation Patient Registry (CFFPR) has chronicled considerable improvement during recent decades in the median predicted survival of US…”
Get full text

Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations by Schechter, Michael S, VanDevanter, Donald R, Pasta, David J, Short, Sarah A, Morgan, Wayne J, Konstan, Michael W

“…There are important gaps in knowledge of the optimal treatment of cystic fibrosis pulmonary exacerbations. Previous observational studies comparing inpatient…”
Get full text

Relationship of Antibiotic Treatment to Recovery after Acute FEV1 Decline in Children with Cystic Fibrosis by Morgan, Wayne J, Wagener, Jeffrey S, Pasta, David J, Millar, Stefanie J, VanDevanter, Donald R, Konstan, Michael W

“…Results: Logistic regression of 9,875 patients showed that new antibiotic treatment was associated with an increased likelihood of recovery to 90% of baseline…”
Get full text

Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis by VanDevanter, Donald R, Pasta, David J, Konstan, Michael W

“…Abstract Background Pulmonary exacerbations (PEx) are important CF clinical events. Methods We studied time to next PEx following intravenous (IV) antibiotic…”
Get full text

Evidence of diminished FEV1 and FVC in 6-year-olds followed in the European cystic fibrosis patient registry, 2007–2009 by VanDevanter, Donald R, Pasta, David J

“…Abstract Background Many infants with cystic fibrosis (CF) exhibit airway inflammation, gas trapping, bronchiectasis, and/or reduced flow, but by age 6 years…”
Get full text

Authors' Reply by Van Devanter, Donald R., Van Dalfsen, Jill M.

Get full text

Authors' Reply by Van Devanter, Donald R., Van Dalfsen, Jill M.

Get full text

Authors' Reply by Van Devanter, Donald R., Van Dalfsen, Jill M.

Get full text

Determination of polymyxin E 1 in rat plasma by high-performance liquid chromatography by Gmur, Dennis J, Bredl, Charles R, Steele, Sharon J, Cai, Shaopei, VanDevanter, Donald R, Nardella, Pasqua A

“…A precise and accurate HPLC assay for polymyxin E 1 in rat and dog plasma has been validated. Samples and standards are extracted from plasma with a 96-well C…”
Get full text

Elimination of Extrachromosomally Amplified MYC Genes from Human Tumor Cells Reduces their Tumorigenicity by Von Hoff, Daniel D., McGill, John R., Forseth, Barbara J., Davidson, Karen K., Bradley, Thomas P., Van Devanter, Donald R., Wahl, Geoffrey M.

“…Oncogene amplification has been observed in a broad spectrum of human tumors and has been associated with a poor prognosis for patients with several different…”
Get full text